Opioid analgesia: New insights

European Journal of Palliative Care

Volumn 13, Issue 5, 2006, Pages 185-187

  Klepstad, Pål ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33748714125     PISSN: 13522779     EISSN: 14790793     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Klepstad P, Borchgrevink PC, Dale O et al. Relations between serum concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide and clinical observations. A prospective survey in 300 cancer patients. Acta Anaesthesiol Scand 2003; 47: 725-731.
2. Klepstad P, Kaasa S, Borchgrevink PC. Start of oral morphine to cancer patients: effective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by morphine. Eur J Clin Pharmacol 2000; 55: 713-719.
3. Cherny N, Ripamonti C, Pereira J et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 2001; 19: 2542-2554.
4. Lötsch J, Skarke C, Liefhold J, Geisslinger G. Genetic predictors of the clinical response to opioid analgesics. Clin Pharmacokinet 2004; 43: 983-1013.
5. Klepstad P, Dale O, Skorpen F, Borchgrevink PC, Kaasa S. Genetic variability and clinical efficacy of morphine. Acta Anaesthesiol Scand 2005; 49: 902-908.
6. Leander JD. Buprenorphine has potent kappa receptor antagonist activity. Neuropharmacology 1987; 26: 1445-1447.
7. Huang P, Kehner GB, Cowan A, Liu-Chen LY. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent agonist. J Pharmacol Exp Ther 2001; 297: 688-695.
8. Ross FB, Wallis SC, Smith MT. Co-administration of sub-antinociceptive doses of oxycodone and morphine produces marked antinociceptive synergy with reduced CNS side-effects in rats. Pain 2000; 84: 421-428.
9. Russell RD, Chang KW. Alternated delta and mu receptor activation: a stratagem for limiting opioid tolerance. Pain 1989; 36: 381-389.
10. Pasternak GW. Molecular biology of opioid analgesia. J Pain Symptom Manage 2005; 29: S2-S9.
11. Bolan EA, Tallrida RJ, Pasternak GW. Synergy between μ opioid ligands. Evidence for functional interactions among μ opioid receptor subtypes. J Pharmacol Exp Ther 2002; 303: 557-562.
12. Ebert B, Andersen S, Krogsgaard-Larsen P. Ketobemidone, methadone and pethidine are non-competitive N-methyl-D-aspartate (NMDA) antagonists in the rat cortex and spinal cord. Neurosci Lett 1995; 187: 165-168.
13. Pasternak GW. Incomplete cross tolerance and multiple mu opioid peptide receptors. Trends Pharmacol Sci 2001; 22: 67-70.
14. Rossi GC, Leventhal L, Pan YX et al. Antisense mapping of MOR-1 in rats: distinguishing between morphine and morphine-6-glucuronide antinociception. J Pharmacol Exp Ther 1997; 281: 109-114.
15. Pan YX, Xu J, Mahurter L et al. Identification and characterization of two human mu opioid receptor splice variants, hMOR-10 and hMOR-1X. Biochem Biophys Res Comm 2003; 301: 1057-1061.
16. Frank Skorpen. Personal communication.
17. Hoehe MR, Köpke K, Wendel B et al. Sequence variability and candidate gene analysis in complex disease: association of μ opioid receptor gene variation with substance dependence. Hum Mol Genet 2000; 9: 2895-2908.
18. Befort K, Filiol D, Decalliot FM et al. A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling. J Biol Chem 2001; 276: 3130-3137.
19. Lötsch J, Skarke C, Grösch S et al. The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics 2002; 12: 3-9.
20. Skarke C, Darimont J, Schmidt H, Geisslinger G, Lötsch J. Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers. Clin Pharmacol Ther 2003; 73: 107-121.
21. Lötsch J, Zimmerman M, Darimont J et al. Does the A118G polymorphism at the μ-opioid receptor gene protect against morphine-6-glucuronide toxicity? Anesthesiology 2002; 97: 814-819.
22. Klepstad P, Rakvåg TN, Kaasa S et al. The 118 A>G polymorphism in the human μ-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand 2004; 48: 1232-1239.
23. Ross JR, Ruttler D, Welsh K et al. Clinical response to morphine in cancer patients and genetic variation in candidate genes. Pharmacogenomics J 2005; 5: 324-336.
24. Zubieta JK, Dannals RF, Frost JJ. Gender and age influences on human brain mu-opioid receptor binding measured by PET. Am J Psychiatry 1999; 156: 842-848.
25. Kraus J, Borner C, Giannini E et al. Regulation of mu-opioid receptor gene transcription by interleukin-4 and influence of an allelic variation within a STAT6 transcription factor binding site. J Biol Chem 2001; 276: 43901-43908.
26. Keith DE, Anton B, Murray SR et al. Mu-opioid receptor internalization: opiate drugs have differential effects on a conserved endocytic mechanism in vitro and in the mammalian brain. Mol Pharmacol 1998; 53: 377-384.
27. Bohn LM, Lefkowitz RJ, Gainetdinov RR et al. Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science 1999; 286: 2495-2498.